FLNA — FILANA THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1069530 ·
Last close
$0.75
Market Cap
$36.23M
52W High
$4.98
52W Low
$0.67
ADV30
3,658,243
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -9,393,000 | -8,603,000 | 103,903,000 | 82,681,000 | 40,294,000 |
| Mar 2026 | 0 | — | -11,168,000 | -10,331,000 | 108,367,000 | 86,573,000 | 40,226,000 |
| Dec 2025 | 0 | — | -14,288,000 | -12,539,000 | 118,355,000 | 95,502,000 | 43,952,000 |
| Sep 2025 | 0 | — | -11,860,000 | -10,807,000 | 129,733,000 | 106,080,000 | 48,165,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-28,702,000
Investing CF
$-581,000
Financing CF
$-396,000
CapEx
$-558,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.87
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-515,018,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-46,709,000
Pretax Income TTM
$-42,280,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -96,126,000 | -90,973,000 | 118,355,000 | 43,952,000 | 74,403,000 | -32,252,000 |
| Dec 2024 | 0 | -142,279,000 | -24,342,000 | 157,533,000 | 11,829,000 | 145,704,000 | -116,929,000 |
| Dec 2023 | 0 | -107,333,000 | -97,217,000 | 151,663,000 | 14,195,000 | 137,468,000 | -82,025,000 |
| Dec 2022 | 0 | -81,482,000 | -76,246,000 | 234,834,000 | 7,295,000 | 227,539,000 | -77,514,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-31,017,000
OpCashFlow TTM
$0
Assets (Latest)
$234,834,000
Forward EPS
—
Max Pain — expiry 2027-01-15
max pain strike: $1.00 · spot: $0.80 · call oi: 2,092 · put oi: 806
Expected Move to 2027-01-15:
±$0.43
(53.05%) —
implied range
$0.38 –
$1.23
· ATM straddle on $1.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PYRGF | PyroGenesis Canada Inc. | $35.77M | $0.16 | — |
| KPTI | Karyopharm Therapeutics Inc. | $36.74M | $1.62 | — |
| NNVC | NANOVIRICIDES, INC. | $36.76M | $1.44 | — |
| MCRB | Seres Therapeutics, Inc. | $35.36M | $3.52 | — |
| BCTX | BriaCell Therapeutics Corp. | $37.58M | $4.32 | — |
News headlines (Yahoo Finance, 1h cache)
Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
2026-09-22 12:00 · Yahoo
Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update
2026-07-29 12:00 · Yahoo
Filana Therapeutics Reports Q1 2026 Financial Results and Business Update
2026-05-07 12:00 · Yahoo
Data I/O And 2 Other Promising Penny Stocks To Watch
2026-05-29 18:05 · Yahoo
Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII
2026-05-05 12:00 · Yahoo
Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data
2026-04-15 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.